about
Thalidomide and thalidomide analogues for maintenance of remission in Crohn's diseaseThalidomide and thalidomide analogues for induction of remission in Crohn's diseaseMonitoring medicines use: the role of the clinical pharmacologistDrugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risksEpidemiological surveillance of birth defects compatible with thalidomide embryopathy in BrazilComparison of rat and rabbit embryo-fetal developmental toxicity data for 379 pharmaceuticals: on the nature and severity of developmental effects.Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses.Slit2 overexpression results in increased microvessel density and lesion size in mice with induced endometriosis.Specific features of medicines safety and pharmacovigilance in AfricaThalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.Hyperemesis gravidarum in the Medical Birth Registry of Norway - a validity studySuccessful treatment of metastatic hepatic epithelioid hemangioendothelioma with thalidomide: a case report.Chemical exposure during pregnancy and oral clefts in newborns.Thalidomide in the treatment of multiple myeloma.Thalidomide as an anti-cancer agent.Thalidomide: an old drug with new clinical applications.Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries.Are epidemiological approaches suitable to study risk/preventive factors for human birth defects?Pharmacovigilance in oncology: evaluation of current practice and future perspectives.Compatibility of a novel thrombospondin-1 analog with fertility and pregnancy in a xenograft mouse model of endometriosis.Facilitating collaboration and research in sex and gender differences and women's health: year one experiences.Women's perception of risks of adverse fetal pregnancy outcomes: a large-scale multinational survey.Human teratogens update 2011: can we ensure safety during pregnancy?Thalidomide for the treatment of multiple myeloma.Determinants of research engagement in academic obstetrics and gynaecology.Thalidomide for dermatology: a review of clinical uses and adverse effects.Perception of drug teratogenicity among general practitioners and specialists in obstetrics/gynecology: a regional and national questionnaire-based survey.Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.Emerging issues in teratology: an introduction.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.The fate and effects of xenobiotics in human placenta.Dermatologic therapeutics: thalidomide. A practical guide.In silico analysis of enantioselective binding of immunomodulatory imide drugs to cereblon.How to build a humanTreatment of relapsed and refractory myeloma.The use of central nervous system active drugs during pregnancy.Preimplantation stress and development.Thalidomide and misoprostol: Ophthalmologic manifestations and associations both expected and unexpected.The current state of birth outcome and birth defect surveillance in northern regions of the world.
P2860
Q24241489-C14CA773-DF97-48E7-B4DE-8B3F04DC5653Q24241766-0D380594-843F-4B81-A519-D55F620D1DC4Q26829859-7919342E-7531-4830-9769-635E4DA7111BQ26991704-62404E85-2CFC-4993-80FB-BFBB57ACDD34Q28478928-3B546FC2-81C7-4A53-8C69-56C4DF440B78Q31142527-CC0503DD-C73C-49BD-907F-F6B9D3FE9C04Q33753486-9A3724FA-4379-4313-8DFD-20909D91857BQ33829562-B1A86421-3F41-49B6-B67E-E70C8E708F6CQ33949341-7A223784-930F-401D-875E-805A09294007Q34454532-82ADFF0C-3D95-47B2-95F1-6F50F90A6F60Q34457276-3569491D-B475-40EA-BDFA-928E181C25EAQ34499046-3FDD6408-831B-4741-BE21-552E2EBCB407Q34575090-79AEA78F-D6A2-4EC0-93CA-F1C30138381FQ34734291-58B980DD-DB3F-4347-A846-5B01AA3D8379Q34778074-36195B62-4100-4A7A-83A3-451BA568AB15Q34798767-BC842ADF-BA87-4BA1-9175-F39F00D822A6Q35023715-D7340638-9DDF-4AC6-9DA0-9C116454DE6DQ35080369-F60A6F82-A747-4809-94D5-590CDBAC0A2BQ35111899-755C3107-0F9A-4C72-8A98-2EF45EE73B6FQ35183601-F6FC231F-1A1F-42E6-BD89-D1C933792BE3Q35219893-AB7FF787-B847-46E5-95DA-983BF27DDF84Q35332771-21A20956-AC17-4F9E-BE34-B463DDD3E679Q35691721-5C8EA24A-F3E0-4617-A73B-BD0F852742A3Q35815011-B56F45C8-D9C5-453B-A1AB-B784A0B9C286Q35870500-85884BFF-365D-4FCE-94AD-63C1E1472A07Q35991292-54236F08-E5EE-4FBE-B5B9-84C7A15E47DEQ36016846-C1EC6675-E684-44F2-9F82-BA6244598D63Q36105381-4FE0FC1E-DE19-4D03-A8B8-2C39DC7615BDQ36171864-B4A4499F-9287-4B34-88A5-8601EF99FD8CQ36377691-424C25B7-98B0-4651-82AD-971604E29DDDQ36612613-DDF474CB-0E90-4A68-98F5-028D3254DE42Q36835803-4FF53ACB-3BA6-496D-B7B5-309FC51FB6FEQ36986014-915AF89B-6AFE-4E04-ADE1-E3615BC846B6Q37104408-86825F63-460B-4437-BF2C-2A7CB6156A84Q37201245-8070D1E5-0CFF-40CE-9802-BD7C9283142BQ37209929-A0F91157-919C-419A-AF3F-9ABCF585ABFAQ37280003-7E4A9838-26C5-4E1A-8356-AA6A7CB49153Q37298217-B91FC661-D50B-4250-AFEB-BF709FAC9824Q37565355-0A2A335F-F242-4627-85E9-036657881CBEQ37665898-0474985C-4317-43D1-8A2F-262F0C0734BB
P2860
description
article publié dans la revue scientifique The Lancet
@fr
im Dezember 1961 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 1961
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@en
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@nl
type
label
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@en
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@nl
prefLabel
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@en
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@nl
P1433
P1476
THALIDOMIDE AND CONGENITAL ABNORMALITIES
@en
P2093
W.G. Mcbride
P356
10.1016/S0140-6736(61)90927-8
P407
P577
1961-12-01T00:00:00Z